INT11510

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.52
First Reported 1980
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 28
Total Number 28
Disease Relevance 12.71
Pain Relevance 9.16

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Gh) signal transduction (Gh) mitochondrion (Gh)
extracellular space (Gh) extracellular region (Gh) plasma membrane (Gh)
Anatomy Link Frequency
plasma 4
pituitary 4
autonomic 2
Gh (Mus musculus)
Pain Link Frequency Relevance Heat
Clonidine 43 100.00 Very High Very High Very High
noradrenaline 14 100.00 Very High Very High Very High
agonist 40 99.78 Very High Very High Very High
Dopamine 27 99.08 Very High Very High Very High
narcan 17 99.02 Very High Very High Very High
Cluster headache 7 98.00 Very High Very High Very High
Kinase C 6 97.96 Very High Very High Very High
opiate 7 96.52 Very High Very High Very High
antagonist 35 96.36 Very High Very High Very High
Serotonin 5 95.72 Very High Very High Very High
Disease Link Frequency Relevance Heat
Disease 55 100.00 Very High Very High Very High
Multiple System Atrophy 20 100.00 Very High Very High Very High
Eating Disorder 6 99.76 Very High Very High Very High
Obesity 36 99.70 Very High Very High Very High
Autonomic Nervous System Disease 13 99.64 Very High Very High Very High
Bronchopulmonary Dysplasia 20 99.48 Very High Very High Very High
Syndrome 48 99.28 Very High Very High Very High
Galactorrhea 12 98.84 Very High Very High Very High
Targeted Disruption 8 98.28 Very High Very High Very High
Cluster Headache 7 98.00 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Pegvisomant is an engineered GH analog that antagonizes GH at the receptor site, and thus prevents endogenous GH activation of its receptor and subsequent downstream signaling.
Negative_regulation (prevents) of Positive_regulation (activation) of GH
1) Confidence 0.52 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721386 Disease Relevance 0.39 Pain Relevance 0.23
Propionate and butyrate at 10 mmol/l, however, not only suppressed basal GH release but also significantly reduced the GH increase induced by 10 nmol/l of GHRH.
Negative_regulation (reduced) of Positive_regulation (increase) of GH
2) Confidence 0.41 Published 1999 Journal Domest. Anim. Endocrinol. Section Abstract Doc Link 10484133 Disease Relevance 0 Pain Relevance 0.39
With chronic therapy, 24-h mean levels were significantly suppressed, and the GH stimulability of thyrotrophin-releasing hormone and growth-hormone-releasing hormone (pl-44) was markedly reduced.
Negative_regulation (reduced) of Positive_regulation (stimulability) of GH
3) Confidence 0.39 Published 1986 Journal Scand. J. Gastroenterol. Suppl. Section Abstract Doc Link 2876499 Disease Relevance 0.26 Pain Relevance 0.13
Elevated GH levels at baseline occurred in four out of five female subjects; this did not affect the clonidine-induced GH release.
Negative_regulation (occurred) of Positive_regulation (Elevated) of GH associated with clonidine
4) Confidence 0.36 Published 1986 Journal Psychoneuroendocrinology Section Abstract Doc Link 3786637 Disease Relevance 0 Pain Relevance 0.58
These results demonstrate reduced pituitary GH response to GH-releasing hormone and to amphetamine in women during the postpartum period, confirming the peculiarity of the hypothalamopituitary component.
Negative_regulation (reduced) of Positive_regulation (response) of GH in pituitary
5) Confidence 0.33 Published 1992 Journal Gynecol. Obstet. Invest. Section Abstract Doc Link 1563655 Disease Relevance 0 Pain Relevance 0.22
A lack of growth hormone (GH) increase after clonidine infusion is found in patients with MSA, but not in those with IPD or with pure autonomic failure.
Negative_regulation (lack) of Positive_regulation (increase) of growth hormone in autonomic associated with autonomic nervous system disease, disease, multiple system atrophy and clonidine
6) Confidence 0.31 Published 2000 Journal J. Neurol. Section Abstract Doc Link 11151417 Disease Relevance 1.43 Pain Relevance 0.45
In 2-h static incubation experiments, norepinephrine and the alpha-2 agonist clonidine decreased basal GH release and the GH responses to stimulation by the dopamine D1 agonist SKF38393 and two native gonadotropin-releasing hormones (GnRH).
Negative_regulation (decreased) of Positive_regulation (responses) of GH associated with dopamine, agonist and clonidine
7) Confidence 0.30 Published 2000 Journal J. Neuroendocrinol. Section Abstract Doc Link 10718929 Disease Relevance 0 Pain Relevance 0.33
Norepinephrine also reduced GH responses to the adenylate cyclase activator forskolin, two protein kinase C (PKC) activators (phorbol ester and synthetic diacylglycerol), and two Ca2+ ionophores (ionomycin and A23187).
Negative_regulation (reduced) of Positive_regulation (responses) of GH associated with kinase c
8) Confidence 0.30 Published 2000 Journal J. Neuroendocrinol. Section Abstract Doc Link 10718929 Disease Relevance 0 Pain Relevance 0.36
These results demonstrate reduced pituitary GH response to GH-releasing hormone and to amphetamine in women during the postpartum period, confirming the peculiarity of the hypothalamopituitary component.
Negative_regulation (reduced) of Positive_regulation (response) of GH in pituitary
9) Confidence 0.29 Published 1992 Journal Gynecol. Obstet. Invest. Section Abstract Doc Link 1563655 Disease Relevance 0 Pain Relevance 0.22
Specifically, they found a linear relation between the decrease in IGF-I and the increase in GH burst amplitude.
Negative_regulation (decrease) of Positive_regulation (increase) of GH
10) Confidence 0.28 Published 2006 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676637 Disease Relevance 0.25 Pain Relevance 0.10
The mean GH increase after 18 months was 33.8 ?
Negative_regulation (33.8) of Positive_regulation (increase) of GH
11) Confidence 0.28 Published 2006 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676637 Disease Relevance 0.33 Pain Relevance 0.12
Clonidine induced sharp, marked reductions of NE, CRT and DBP, plus a sudden increase of GH, in all the patients during exacerbation periods.
Negative_regulation (reductions) of Positive_regulation (increase) of GH associated with clonidine
12) Confidence 0.28 Published 1987 Journal Psychoneuroendocrinology Section Abstract Doc Link 3602260 Disease Relevance 0.24 Pain Relevance 0.31
With increasing age, GH pulse amplitude is markedly reduced, and there is a loss of the nocturnal GH increase, but the number of GH pulses does not change greatly (Ho et al 1987).
Negative_regulation (loss) of Positive_regulation (increase) of GH
13) Confidence 0.27 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2544358 Disease Relevance 0.08 Pain Relevance 0
Compared to matched controls the depressed patients showed attenuated CLON-induced GH responses before treatment with MOC or MAP.
Negative_regulation (attenuated) of Positive_regulation (induced) of GH associated with clonidine
14) Confidence 0.27 Published 1990 Journal J. Neural Transm. Suppl. Section Abstract Doc Link 1965198 Disease Relevance 0.26 Pain Relevance 0.44
Note the GH increase after TRH (200 ?
Negative_regulation (Note) of Positive_regulation (increase) of GH
15) Confidence 0.25 Published 2007 Journal Pituitary Section Body Doc Link PMC2045692 Disease Relevance 0.41 Pain Relevance 0
The patients reported here all exhibited GH increase after TRH, and two had mild hyperprolactinemia.
Negative_regulation (exhibited) of Positive_regulation (increase) of GH associated with galactorrhea
16) Confidence 0.25 Published 2007 Journal Pituitary Section Body Doc Link PMC2045692 Disease Relevance 1.37 Pain Relevance 0
Previously, we have shown that in the opposite extremes of nutritional status (obesity and anorexia nervosa [AN]), the growth hormone (GH) response to GH-releasing hormone (GHRH) is not inhibited by the ingestion of a normal 800-kcal meal at noon.
Negative_regulation (inhibited) of Positive_regulation (response) of GH associated with obesity and eating disorder
17) Confidence 0.21 Published 2001 Journal Metab. Clin. Exp. Section Abstract Doc Link 11288030 Disease Relevance 0.69 Pain Relevance 0.36
Previously, we have shown that in the opposite extremes of nutritional status (obesity and anorexia nervosa [AN]), the growth hormone (GH) response to GH-releasing hormone (GHRH) is not inhibited by the ingestion of a normal 800-kcal meal at noon.
Negative_regulation (inhibited) of Positive_regulation (response) of growth hormone associated with obesity and eating disorder
18) Confidence 0.21 Published 2001 Journal Metab. Clin. Exp. Section Abstract Doc Link 11288030 Disease Relevance 0.69 Pain Relevance 0.36
We found that NAL inhibited the paradoxical postprandial GH increase only in pre-BPD subjects (GH area under the concentration time curve [AUC] in microg/L/90 min)-before meal: after GHRH 237.54 +/- 62.28, after NAL + GHRH 699.2 +/- 271.57; after meal: after GHRH 575.46 +/- 109.68, after NAL + GHRH 156.17 +/- 24.96.
Negative_regulation (inhibited) of Positive_regulation (increase) of GH associated with bronchopulmonary dysplasia
19) Confidence 0.21 Published 2001 Journal Metab. Clin. Exp. Section Abstract Doc Link 11288030 Disease Relevance 0.88 Pain Relevance 0.39
Previously, we have shown that in the opposite extremes of nutritional status (obesity and anorexia nervosa [AN]), the growth hormone (GH) response to GH-releasing hormone (GHRH) is not inhibited by the ingestion of a normal 800-kcal meal at noon.
Negative_regulation (inhibited) of Positive_regulation (response) of GH associated with obesity and eating disorder
20) Confidence 0.21 Published 2001 Journal Metab. Clin. Exp. Section Abstract Doc Link 11288030 Disease Relevance 0.69 Pain Relevance 0.36

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox